Aptinyx — Investor Presentation (June 2021)
57 slides from Aptinyx's investor presentation, Jun 15, 2021
Slide 1: Innovative Therapies for Disorders of the Brain and Nervous System
Innovative Therapies for Disorders of the Brain and Nervous System Corporate Presentation June 2021 Nasdaq: APTX
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jur
Slide 3: Passion. Learning. Advancing. This is how we define progress
PA S S I O N . LEARNING.ADVANCING. THIS IS HOW WE DEFINE PROGRESS TO IMPACT PATIENT LIVES 3 June 2021
Slide 4: Multiple near-term catalysts with Phase readouts starting 1H 2022
4 June 2021 Multiple near-term catalysts with 4 Phase 2 readouts starting 1H 2022 4 June 2021
Slide 5: Novel modulation of the NMDA receptor at a unique domain
5 June 2021 Aptinyx compounds work through novel modulation of the NMDA receptor at a unique domain distinct from existing drugs. 5 June 2021 This approach can result in optimal modulation of the NMDA receptor, achieving therapeutic activity while providing a favorable safety and tolerability profil
Slide 6: Our approach is multidimensional
Our approach is multidimensional Enhancing synaptic plasticity to achieve therapeutic effects across disease areas CHRONIC PAIN COGNITION PSYCHIATRY 6 June 2021
Slide 7: Our mission: innovative therapies for CNS disorders
7 June 2021 OUR MISSION is to discover and develop innovative therapies for challenging disorders of the brain and nervous system Breadth of activity and encouraging efficacy data across multiple CNS indications with high unmet medical need Differentiated safety profile observed across hundreds of h
Slide 8: Encouraging activity across multiple high-value indications
Encouraging activity observed to date across multiple high-value indications demonstrates potential for meaningful value creation 8 June 2021 NYX-2925 in CHRONIC PAIN NYX-783 in PTSD NYX-458 in COGNITIVE IMPAIRMENT Clear, reproducible activity across preclinical pain models Favorable safety profile
Slide 9: Advancing a pipeline of innovative CNS therapies
INDICATION PRECLINICAL/ IND ENABLING PHASE 1 PHASE 2 PHASE 3 REGISTRATION/ COMMERCIAL CHRONIC PAIN PROGRAM NYX-2925 Fibromyalgia Painful Diabetic Peripheral Neuropathy (DPN) PSYCHIATRY PROGRAM NYX-783 Post-Traumatic Stress Disorder (PTSD) NEUROLOGY PROGRAM NYX-458 Cognitive Impairment in Parkinson’s
Slide 10: Experienced management team and board
Experienced management team and a board of highly regarded healthcare investors and leaders 10 Patrick Enright (Chairman) Founder & Managing Director BOARD OF DIRECTORS Rachel Sherman, MD, MPH Former FDA Principal Deputy Commissioner Henry Gosebruch EVP, Chief Strategy Officer, AbbVie Norbert Riedel
Slide 11: The NMDA receptor: essential for normal CNS function
June 2021 11 The NMDA receptor Essential for normal CNS function NMDA receptors are widely distributed at all stages of development and play a critical role in higher level brain functions, including For decades, researchers have attempted to discover and develop compounds that target NMDA receptors
Slide 12: NMDA receptor modulation: a novel and differentiated approach
June 2021 12 NMDA receptor modulation: A novel and differentiated approach to restoring normal balance in the CNS NMDA receptor modulation: A novel and differentiated approach to restoring normal balance in ON OFF ANTAGONIST OVERACTIVATION INHIBITION AGONIST DISSOCIATION PSYCHOTOMIMETIC ABUSE LIABIL
Slide 13: Modulation of NMDAr enhances synaptic plasticity
Modulation of NMDAr with Aptinyx compounds triggers a neurobiological cascade and enhances synaptic plasticity—the foundation of neural cell communication LTP = long-term potentiation LTD = long-term depression Rapid receptor engagement Long-lasting effects on neural plasticity processes Learning Me
Slide 14: Discovery platform has produced >1,000 unique compounds
NMDAr modulator discovery platform has produced > 1,000 unique compounds Molecules bind at a novel, distinct, newly characterized binding domain Molecules demonstrate high oral bioavailability and stability Molecules have diverse potency, activity, subtype selectivity, and pharmacology/biology profi
Slide 15: NMDA receptors are key targets for CNS disorders with high unmet need
NMDA receptors are key targets for numerous CNS disorders with high unmet medical need June 2021 15 Representing vast commercial opportunity for Aptinyx product candidates Fibromyalgia Up to 15 million People affected in the United States PTSD > 8.5 million Painful DPN ~ 7.5 million Cognitive Impair
Slide 16: Chronic Pain Franchise: NYX-2925 for painful DPN and fibromyalgia
Chronic Pain Franchise: NYX-2925 for Painful Diabetic Peripheral Neuropathy (DPN) & Fibromyalgia June 2021 16
Slide 17: Addressing centralized chronic pain through NMDA modulation
Seeking to address centralized chronic pain conditions through novel NMDA receptor modulation Central processing abnormalities are present in chronic pain conditions Some pain conditions are believed to be primarily centralized pain conditions – e.g., fibromyalgia, phantom limb pain NYX-2925 is desi
Slide 18: Mechanism of NYX-2925 targets aberrant centralized pain processing
Mechanism of NYX-2925 targets aberrant centralized pain processing in chronic pain conditions NORMAL PAIN PROCESSING 1. Stimulus sensed by peripheral nerve 2. Impulses depolarize the dorsal horn, increasing Ca2+ in neurons, causing release of neurotransmitters 3. Signal is sent to the brain via asce
Slide 19: Fibromyalgia and painful DPN
June 2021 19 Fibromyalgia is one of the most common chronic pain conditions Painful DPN is one of the most common complications among patients suffering from diabetes, estimated to affect up to 30% of patients • Both are substantial market opportunities with no adequate therapeutic options Current t
Slide 20: Dysregulation of central pain processing in fibromyalgia and painful DPN
June 2021 20 Dysregulation of central pain processing is evident in patients with fibromyalgia and painful DPN Representing strong scientific rationale for the potential of NYX-2925 Aberrant processing in fibromyalgia — which can be objectively observed with validated biomarkers — results in pain an
Slide 21: Design of Phase 2 neuroimaging biomarker study in fibromyalgia
Week 2 Week 6 Week 4 Day 1 MRI MRI MRI DAILY PAIN SCORE Follow-up Period MRI MRI* Week 1 Week 3 Week 5 Week 7 Day -30 n=22 Screening Period NYX-2925 20 mg q.d. Placebo q.d. Legend: NYX-2925 200 mg q.d. Neuroimaging biomarker changes directly and objectively measure drug activity Design of completed
Slide 22: Effects on objective biomarkers of centralized pain processing
Effects on objective biomarkers demonstrated activity on centralized pain processing and were correlated with effects on patient-reported measures Phase 2 neuroimaging study results: NYX-2925 demonstrated significant effects on primary endpoint, validated biomarkers of pain processing FMRI FINDINGS
Slide 23: Improvements in patient-reported symptoms of fibromyalgia
Average Daily Pain: 19% improvement Worst Daily Pain: 12% improvement FIQR: 16% improvement PROMISFM Fatigue: 9% improvement Phase 2 neuroimaging study results: NYX-2925 demonstrated meaningful improvements in patient-reported symptoms of fibromyalgia Average Daily Pain Worst Daily Pain *Total FIQR
Slide 24: Phase 2 findings on biomarkers and patient-reported outcomes
Phase 2 study findings demonstrate effects on neuroimaging biomarkers and patient-reported outcomes Study results inform follow-up Phase 2b study of NYX-2925 in fibromyalgia patients June 2021 24 NYX-2925 was well tolerated in the study with no SAEs observed Effects on biomarkers demonstrated activi
Slide 25: First-in-patient Phase 2 study in painful DPN
Completed first-in-patient Phase 2 study of NYX-2925 in patients with painful DPN June 2021 25 Phase 2 study was the first time NYX-2925 was evaluated in patients with painful DPN Placebo QD (n=72) 4-WEEK TREATMENT PERIOD Inclusion/exclusion eligibility Analgesic washout - Patients were allowed to m
Slide 26: Phase 2 DPN top-line results
Phase 2 DPN top-line results: NYX-2925 demonstrated analgesic signal, with greater separation in patients not on concomitant analgesics Efficacy Population Not on Concomitant Analgesic (n=148) Total Efficacy Population (n=300) CHANGE IN AVERAGE DAILY PAIN (PRIMARY EFFICACY ENDPOINT) 25% reduction in
Slide 27: Change in average daily pain by DPN duration
Change in Average Daily Pain (Baseline to Week 4) by DPN Duration -1.62 -1.51 -1.77 -1.93 -2.12 -1.26 -1.26 -1.04 -0.72 -0.93 -2.5 -2 -1.5 -1 -0.5 0 ≥ 1 yrs (n=275) ≥ 2 yrs (n=204) ≥ 3 yrs (n=151) ≥ 4 yrs (n=127) ≥ 5 yrs (n=95) Change in NRS (0 - 10) Pain Score from Baseline 50mg Placebo ** * n=46 n
Slide 28: Greater analgesic activity in advanced DPN patients
35% reduction in pain 1.8-point separation from placebo Evidence of greater analgesic activity in Advanced DPN patients provides important inclusion/exclusion criteria learnings for future studies Encouraging and clinically meaningful effects observed in advanced DPN population—with no plateau in fo
Slide 29: Effect in advanced DPN consistent across endpoints
Effect of NYX-2925 in advanced DPN patients was consistent across endpoints in the study *Retrospective analysis of advanced DPN population includes patients who had DPN for ≥ 4 years Pain on Walking: 32% Improvement 1.1-point separation vs. placebo Change in Average Pain on Walking (NRS) Score from
Slide 30: Key study findings support further development in painful DPN
Key study findings provide foundation for further development of NYX-2925 for painful DPN Patients with advanced DPN showed the greatest treatment benefit Mechanism of NYX-2925 addresses the increasing central manifestation of pain perception and processing associated with the prolonged chronic pain
Slide 31: Phase 2b studies of NYX-2925 in fibromyalgia and painful DPN
PAINFUL DPN Advanced DPN population (4+ years) No concomitant analgesics Primary endpoint: Change in average daily pain on the Numerical Rating Scale (NRS) Other endpoints: Worst daily pain, daily sleep interference, pain on walking Phase 2b studies of NYX-2925 in 2 chronic pain indications: fibromy
Slide 32: Favorable tolerability and PK of NYX-2925 in Phase 1
Favorable tolerability and dose-proportional PK of NYX-2925 observed in 84-subject Phase 1 study Drug is cleared within 24 hours No significant accumulation after 7 daily doses AUC and Cmax are directly proportional to unit dose No impact on AUC in fed vs. fasted state Brain exposure is ample and pr
Slide 33: Development summary of NYX-2925
Development summary of NYX-2925 for painful DPN and fibromyalgia ✓ CLEAR PRECLINICAL ACTIVITY – robust, long-lasting effects seen across various models of neuropathic pain ✓ COMPLETED THREE PHASE 1 STUDIES – favorable tolerability, PK, and CNS exposure observed, as well as evidence of activity and N
Slide 34: Psychiatry Franchise: NYX-783 for PTSD
Psychiatry Franchise: NYX-783 for Post-Traumatic Stress Disorder (PTSD) June 2021 34
Slide 35: PTSD prevalence and unmet need
50-66% also battle simultaneous addiction to alcohol and drugs Numerous causes of PTSD Elevated suicide rates among PTSD sufferers June 2021 35 PTSD Estimated lifetime prevalence of 6.8% ONLY 2 approved therapies both approved 20+ years ago Car accidents War combat Criminal assault Natural disaster
Slide 36: Differentiated approach targeting underlying learning and memory dysfunction
ANTIDEPRESSANTS – Mood ANXIOLYTICS – Severe anxiety-related complications HYPNOTICS – Nightmares – Sleep disturbances Differentiated approach to targeting PTSD: Addressing the underlying learning & memory dysfunction June 2021 36 CURRENT APPROACHES Target symptoms OUR APPROACH Targets underlying dys
Slide 37: PTSD symptom clusters captured in the CAPS-5
PTSD symptoms and diagnosis characterized by four core symptom clusters captured in the CAPS-5 June 2021 Along with these symptom clusters, a diagnosis of PTSD typically requires: • Symptoms for ≥ 1 month • Symptoms cause impairment in important areas of function Arousal & Reactivity • Exaggerated s
Slide 38: Preclinical activity of NYX-783 across PTSD-related models
Significantly improves negative mood/affect in Porsolt forced swim model Demonstrates robust enhancement of total sleep, non-REM sleep, and REM sleep in sleep-deprivation model Demonstrates activity in Novel Object Recognition model, enhancing recognition memory Enhances extinction of alcohol-seekin
Slide 39: Proof-of-concept study with clinically meaningful improvements
Compelling proof-of-concept study completed with clinically meaningful improvements observed across endpoints 39 June 2021 Large proportion of patients achieved a clinically meaningful response with 4 weeks of treatment Consistent improvements observed on CAPS-5 symptom cluster scores Improvements o
Slide 40: Phase 2 PTSD study design
Phase 2 PTSD Study Design June 2021 CAPS-5(Clinician Administered PTSD Scale – DSM 5th Edition) | DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) | PBO (placebo) *160 subjects randomized in total. 7 were under a prior protocol version which included a weekly dose; therefore, those 7 su
Slide 41: Phase 2 efficacy results by stage
Stage 1 (4 weeks) ITT Population Stage 2 (4 weeks) ITT - PBO Non-Responders MMRM LSM (SE) Change from Baseline Randomized, Parallel Design Portion MMRM LSM (SE) Change from New Baseline Following 4 Weeks of Placebo in Stage 1 Combined Stage 1 + Stage 2 p-value vs. Placebo Placebo NYX-783 50 mg NYX-7
Slide 42: Clinically meaningful change on CAPS-5 Total score
43% 45% 74% Placebo (n=86) 10mg NYX-783 (n=20) 50mg NYX-783 (n=19) p=0.01 vs. placebo STAGE 1 (WEEK 4) CAPS-5 TOTAL SCORE – Clinically Reliable Change June 2021 42 NYX-783 exhibited clinically meaningful change from baseline on CAPS-5 Total score Significantly greater proportion of patients demonstr
Slide 43: Percent change from baseline on CAPS-5 scores
-35% -29% -43% Stage 1 - Week 4 Placebo (n=103) 10 mg NYX-783(n=24) 50 mg NYX-783(n=26) Much greater improvement in percent change from baseline with NYX-783 50 mg on CAPS-5 Total, Arousal & Reactivity, and Negative Cognitions & Mood 43 June 2021 CAPS-5 Total CAPS-5 (Clinician Administered PTSD Scal
Slide 44: CAPS-5 changes in line with currently used PTSD therapies
June 2021 44 Observed changes from baseline to week 4 on CAPS-5 Total score in-line with observed changes for therapies currently used to treat PTSD ++Only Sertraline and Paroxetine are approved by the FDA for use in PTSD – All other therapies listed are used off-label or are currently in developmen
Slide 45: Final design of Phase 2b program following FDA Type C meeting
Final design of Phase 2b program following Type C meeting with FDA 10-WEEK TREATMENT PERIOD ~300 patients - Civilian and military PTSD 10 weeks of daily treatment Randomized, parallel, double-blind design No concomitant PTSD pharmacotherapies (SSRIs) Primary endpoint: CAPS-5 Total score Key secondar
Slide 46: Results support advancing NYX-783 into registration-supportive studies
Results from Phase 2 exploratory study support advancing NYX-783 into registration-supportive studies in PTSD Study results inform final design of Phase 2b and future development path of NYX-783 in PTSD. June 2021 46 NYX-783 was well tolerated in the study with no drug-related SAEs and an overall AE
Slide 47: Favorable tolerability and PK of NYX-783 in Phase 1
Favorable tolerability and dose-proportional PK of NYX-783 observed in 70-subject Phase 1 study NYX-783 50 mg PO SINGLE ASCENDING DOSE PLASMA PK MULTIPLE ASCENDING DOSE PLASMA PK CSF CONCENTRATION Predictable and dose-proportional PK Cleared from plasma in 24 hours No significant accumulation with r
Slide 48: Development summary of NYX-783 for PTSD
Development summary of NYX-783 for PTSD June 2021 ✓ CLEAR PRECLINICAL ACTIVITY in fear extinction and other psychiatric models ✓ FAVORABLE TOLERABILITY, PK, AND CNS EXPOSURE demonstrated in completed Phase 1 study in humans ✓ COMPLETED PHASE 2 STUDY – NYX-783 exhibited symptom reduction and demonstr
Slide 49: Neurology Franchise: NYX-458 for cognitive impairment in PD and DLB
Neurology Franchise: NYX-458 for Cognitive Associated with Parkinson’s Disease and Dementia with Lewy Bodies June 2021 49
Slide 50: Cognitive impairment in Parkinson's and Lewy body dementia
50 Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies (together referred to as Lewy body dementia) 1 therapy approved to date, Exelon®, which has demonstrated limited benefit in patients June 2021 ~1.4 million people suffering from Lewy body dementia in the United States 15–20
Slide 51: NYX-458 enhances NMDA receptor activity in α-synuclein disorders
NYX-458 enhances NMDA receptor activity and has the potential to address cognitive impairment in α-synuclein disorders Alpha-synuclein increases in Parkinson’s disease and dementia with Lewy bodies result in decreased NMDAr activity CLEAR MECHANISTIC RATIONALE Parkinson’s disease and dementia with L
Slide 52: Pro-cognitive activity in preclinical models including non-human primate
NYX-458 exhibits clear pro-cognitive activity in preclinical models, including translatable non-human primate model of Parkinson’s disease VARIABLE DELAYED RESPONSE (VDR) Activity observed across cognitive domains Recovered effects after re-induced impairment Sustained effects with repeat dosing Eff
Slide 53: Favorable tolerability and PK of NYX-458 in Phase 1
Favorable tolerability and dose-proportional PK of NYX-458 observed in 62-subject Phase 1 study SINGLE ASCENDING DOSE PLASMA PK MULTIPLE ASCENDING DOSE PLASMA PK CSF CONCENTRATION NYX-458 10 mg PO Predictable and dose-proportional PK Cleared from plasma in 24 hours No meaningful accumulation with re
Slide 54: Phase 2 exploratory study of NYX-458
Phase 2 exploratory study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies June 2021 54 Data from exploratory Phase 2 study expected 2H 2022 Placebo QD 12-WEEK TREATMENT PERIOD • 50-85 years of age • PD-MCI, PDD, DLB, MCI-LB • CGI-S at least 3 (mil
Slide 55: Development summary of NYX-458
Development summary of NYX-458 for cognitive impairment in Parkinson’s disease and dementia with Lewy bodies ✓ CLEAR PRECLINICAL ACTIVITY in numerous rodent models ✓ REVERSAL OF COGNITIVE DEFICITS in translatable non-human primate model of Parkinson’s disease ✓ COMPLETED PHASE 1 STUDY – favorable to
Slide 56: Strong cash position with multiple upcoming catalysts
Supported by strong cash position with multiple upcoming catalysts across programs Data readout from Phase 2b fibromyalgia study – 1H 2022 Data readout from Phase 2b painful DPN study – 1H 2022 NYX-2925 in CHRONIC PAIN NYX-458 in COGNITIVE IMPAIRMENT Data readout from Phase 2a Parkinson’s disease an
Slide 57: NMDA receptors implicated in a variety of neurological and psychiatric disorders
NMDA receptors have been implicated in the pathophysiology of a variety of neurological and psychiatric disorders 57 Alzheimer’s Disease Depression Bipolar Disorder Substance Abuse Autism Spectrum Disorders Schizophrenia Cerebral Ischemia Huntington’s Disease Traumatic Brain Injury Anti-NMDAR Enceph